Skip to content
PeptideAgent

Compounding pharmacies in Mississippi

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The Mississippi Board of Pharmacy regulates compounding pharmacies in Mississippi. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Mississippi at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Mississippi

No verified compounding pharmacies serving Mississippi are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Mississippi

The Mississippi Board of Pharmacy regulates pharmacies under the Mississippi Pharmacy Practice Act (Miss. Code sections 73-21-69 to 73-21-129) and the Mississippi Pharmacy Practice Regulations (Title 30, Part 3001), including Article VI on pharmacy permits. Under section 73-21-106, any pharmacy outside Mississippi that ships, mails, or delivers prescription drugs to Mississippi residents must hold a nonresident permit, submit its latest home-state inspection report, and designate a pharmacist-in-charge who holds a Mississippi pharmacist license as well as a home-state license. The Board has published guidance on semaglutide compounding stating that semaglutide salt forms (such as semaglutide sodium or acetate) do not meet federal requirements because they are not the active ingredient in the approved product. Mississippi has no state bulks list; peptide eligibility follows the federal 503A framework. Section 73-21-106 was reenacted and amended by House Bill 856 of the 2025 Regular Session (section 18), effective on passage, and the same act moved the Pharmacy Practice Act repealer to July 1, 2029 ("Sections 73-21-71 through 73-21-129 ... shall stand repealed on July 1, 2029"), so the nonresident permit requirement is in force as of this record's check on 2026-09-22 and stays in force unless the Legislature lets the Act lapse on that date. [1] [2] [3] [4] [5] [6]

Compounded GLP-1 access in Mississippi

A telehealth GLP-1 program must use a Mississippi-licensed physician and a pharmacy holding a Mississippi permit or nonresident permit. [2] [5] [9]

Research use only sellers in Mississippi

The Mississippi Pharmacy Practice Act limits dispensing of prescription drugs to permitted pharmacies and licensed practitioners, so sellers of "research use only" injectable peptides to Mississippi consumers are not lawful dispensers in the state. On August 19, 2026 the Mississippi State Board of Medical Licensure, Board of Nursing, and Board of Pharmacy issued a joint statement that no healthcare provider may compound, administer, dispense, prescribe, advise on, recommend, or supply a non-FDA-approved or research-grade peptide, or delegate those acts to another provider. The boards said a patient consent form calling a product research grade does not remove the provider's professional or legal liability, and providers must buy all prescription products, drugs, and ingredients from entities permitted by the Mississippi Board of Pharmacy. [1] [10] [11]

Mississippi notes on specific peptides

  • Semaglutide: Available branded by prescription from a Mississippi-licensed physician, including by telemedicine. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025, and the Mississippi Board of Pharmacy has said salt forms such as semaglutide sodium or acetate may not be used. [5] [9]

How to check a compounding pharmacy in Mississippi

  1. Search the Mississippi Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Mississippi requires before it ships to you. [1] [2] [3] [4] [5] [6]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Mississippi. [1] [10] [11]

Common questions in Mississippi

Can an out-of-state pharmacy ship compounded peptides to me in Mississippi?

Only with a Mississippi nonresident permit under Miss. Code section 73-21-106. The pharmacy must also name a pharmacist-in-charge licensed in both Mississippi and its home state. Check the Board of Pharmacy license lookup before ordering. [1] [2]

Is compounded semaglutide still available in Mississippi?

Only in limited, patient specific cases after the federal shortage allowances ended in 2025, and never from semaglutide salt forms, which the Mississippi Board of Pharmacy has said do not meet federal requirements. [5] [9]

Can a Mississippi pharmacy compound BPC-157?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [6] [7] [8]

All peptide legal questions for Mississippi

Sources

  1. [1]Mississippi Board of Pharmacy
  2. [2]Miss. Code section 73-21-106, Registration requirement for nonresident pharmacies
  3. [3]Mississippi House Bill 856, 2025 Regular Session (as sent to Governor): reenacts section 73-21-106 and extends the Pharmacy Practice Act repealer to July 1, 2029
  4. [4]Mississippi Pharmacy Practice Regulations (Title 30, Part 3001)
  5. [5]Mississippi Board of Pharmacy: semaglutide compounding guidance
  6. [6]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  7. [7]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  8. [8]FDA: Pharmacy Compounding Advisory CommitteeFDA
  9. [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  10. [10]21 U.S.C. 331, Prohibited acts
  11. [11]Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides (Mississippi Board of Nursing, Board of Pharmacy, State Board of Medical Licensure, August 19, 2026)